Glossary readingAbout 3 min
Learn the language of signaling
Understand receptors, agonists and why a biological signal is not automatically a health benefit.
The research learning room
Follow your
curiosity.
Three trails. A clearer way into the science.
Start with a question, follow a mechanism, and learn where the evidence stops. No prerequisites. No treatment promises.
3 beginner trails5 readings per trailProgress stays on your device
READ → EXPLORE → QUESTION → REVISIT
Education. Research. Perspective. For learning about research only. These simple maps are not medical advice or instructions for treatment. They do not tell you what to take, how much to take, or what to combine. Showing a possible biological process does not prove that it helps people.
Choose a starting point
Learn at your own pace.
Trail 02 · About 23 minutes of summarized reading
Metabolism: Receptors are only the beginning.
Learn how hormone signals affect appetite and blood sugar, and how studies in people test benefits and harms.
What you’ll be able to explainDistinguish receptor activity, trial outcomes, approved products and individual suitability.
- Molecule profileAbout 6 min
Semaglutide: mechanism meets trials
Separate GLP-1 biology from the specific populations, outcomes and safety issues in clinical trials.
- Interactive diagramAbout 4 min
One molecule, two receptor targets
Explore GIP and GLP-1 signaling as parallel interactions, not a guaranteed additive effect.
- Molecule profileAbout 6 min
Tirzepatide: read the study boundaries
Learn how a trial population and a product label constrain what can reasonably be concluded.
- Evidence comparisonAbout 4 min
Compare without choosing a treatment
Compare mechanism, evidence and safety. This exercise is not a recommendation to start or combine medicines.
Go to the original literature
Optional deeper reading. Study titles describe authors’ research—not an endorsement of every conclusion.
Semaglutide · Clinical trial · 2021
Once-Weekly Semaglutide in Adults with Overweight or Obesity.Tirzepatide · Clinical trial · 2022
Tirzepatide Once Weekly for the Treatment of Obesity.